Express Scripts-Anthem Split Could Signal Positive Trend For Biopharma
Express Scripts is losing its biggest customer, which could be a sign that plan sponsors are looking for more control over their pharmacy spending -- bad news for the big PBMs but good news for biopharma?
You may also be interested in...
Express Scripts' plan to purchase medical benefits management company eviCore may give the PBM an opportunity to bring new pricing pressures to the medical benefit drug space.
Price increases generated 100% of net US earnings growth at major biopharma firms in 2016, according to investment analyst report assessing threat of continued pricing pressure.
More than one-third of gross sales for brands is eaten up by rebates, discounts and fees, a study finds, raising questions about whether price concessions provided to payers are ‘flowing to patients,’ PhRMA President Stephen Ubl says.